Our Business

Ariana’s XAI Driven Drug Development Platform :
Accelerated Path From Design to Approval
AI Driven Knowledge Integration and Discovery Platform Aiming at Regulatory Strategy

Robust, explainable XAI integrates a broad range of clinical and multi-omic data, leading to expedited product approval
Integrating 100,000s parameters, starting with as few as 10s of patients

Partnerships

RWE Patients Records

Years of experience

Total Investment

We design Precision Medicine Clinical protocols

We can start our process at the pre-clinical
stage or with as few as 10 patients.

We integrate pre-clinical data, data from
past clinical trials when they exist.

Real World Evidence data from our extensive knowledge base in order to identify biomarkers and design a data enriched clinical protocol.

We collect & generate data

Through our international leading genomic sequencing laboratory partners, we manage the process of acquiring multi-omic data (DNA, RNA, Gut micro biota, single cell RNA expression) immune profiling (FACS) etc. data. We enrich our design using our 160 Million+ Real World Evidence data, including synthetic control arms. The challenge is to analyze and integrate these datasets of diverse patient attributes into logical and actionable “signatures” that support your drug development decisions. Using our KEM® (Knowledge, Extraction, Management) technology, Ariana offers a unique and validated approach to data analysis that guarantees you learn everything you want to know from your data. By working with Ariana, you save money, save time, accelerate your development timelines and preserve patent life. Integrating 100.000s parameters : Robust, eXplainable XAI used to integrate a broad range of clinical and multi-omic data towards precision medicine

Integrate and discover with our XAI Technology

Using our KEM® Al platform and combined analysis,
we identify:

• Optimal dose

• Companion biomarkers and best responders end-points and surrogate endpoints

• Synergistic drug combinations

• Novel indications

Regulatory Strategy

Benefiting from over 10 years of close interactions with the FDA,
we transform findings from the KEM® platform into optimal regulatory strategies for accelerated approval